Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GEMPNASDAQ:NLTXNASDAQ:TELONASDAQ:ZNTL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGEMPGemphire Therapeutics$0.62-4.0%$4.97$0.24▼$1.49$9.25M2.82127,174 shs58,024 shsNLTXNeoleukin Therapeutics$19.50-2.9%$17.79$2.03▼$14.36$183.26M1.1150,104 shs221,816 shsTELOTelomir Pharmaceuticals$1.18+2.6%$2.05$1.12▼$8.40$35.12M-0.9174,431 shs133,417 shsZNTLZentalis Pharmaceuticals$1.26+5.5%$1.32$1.01▼$5.44$90.30M1.591.45 million shs1.70 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGEMPGemphire Therapeutics0.00%+2.84%-6.40%-53.75%-85.70%NLTXNeoleukin Therapeutics0.00%+24.32%-7.97%+155.44%-41.14%TELOTelomir Pharmaceuticals-2.54%-8.00%-46.51%-55.43%-73.44%ZNTLZentalis Pharmaceuticals-4.80%+2.59%-21.71%+14.42%-67.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATELOTelomir Pharmaceuticals2.6213 of 5 stars3.82.00.00.01.90.00.6ZNTLZentalis Pharmaceuticals1.56 of 5 stars3.32.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGEMPGemphire Therapeutics 0.00N/AN/AN/ANLTXNeoleukin Therapeutics 0.00N/AN/AN/ATELOTelomir Pharmaceuticals 3.50Strong Buy$15.001,171.19% UpsideZNTLZentalis Pharmaceuticals 2.50Moderate Buy$8.37566.67% UpsideCurrent Analyst Ratings BreakdownLatest GEMP, ZNTL, NLTX, and TELO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ZNTLZentalis PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.005/15/2025ZNTLZentalis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGEMPGemphire TherapeuticsN/AN/AN/AN/A$0.54 per shareN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/AZNTLZentalis Pharmaceuticals$67.43M1.34N/AN/A$4.73 per share0.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGEMPGemphire Therapeutics-$23.64MN/A0.00∞N/AN/A-419.70%-173.05%N/ANLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ATELOTelomir Pharmaceuticals-$16.53M-$0.42N/AN/AN/AN/A-2,009.40%-1,009.72%8/12/2025 (Estimated)ZNTLZentalis Pharmaceuticals-$165.84M-$3.13N/AN/AN/AN/A-65.48%-51.05%8/8/2025 (Estimated)Latest GEMP, ZNTL, NLTX, and TELO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ZNTLZentalis Pharmaceuticals-$0.67-$0.67N/A-$0.67N/AN/A5/12/2025Q1 2025TELOTelomir Pharmaceuticals-$0.10-$0.07+$0.03-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGEMPGemphire TherapeuticsN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/AZNTLZentalis PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGEMPGemphire TherapeuticsN/A0.670.67NLTXNeoleukin TherapeuticsN/A15.3315.33TELOTelomir PharmaceuticalsN/A0.750.75ZNTLZentalis PharmaceuticalsN/A6.946.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGEMPGemphire Therapeutics17.53%NLTXNeoleukin Therapeutics52.37%TELOTelomir PharmaceuticalsN/AZNTLZentalis PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipGEMPGemphire Therapeutics22.70%NLTXNeoleukin Therapeutics1.58%TELOTelomir PharmaceuticalsN/AZNTLZentalis Pharmaceuticals1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGEMPGemphire Therapeutics914.87 millionN/ANot OptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataTELOTelomir Pharmaceuticals129.76 millionN/AN/AZNTLZentalis Pharmaceuticals16071.95 million70.59 millionOptionableGEMP, ZNTL, NLTX, and TELO HeadlinesRecent News About These CompaniesZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 1, 2025 | globenewswire.comHere's Why We're Watching Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn SituationJune 26, 2025 | finance.yahoo.comZentalis Pharmaceuticals shareholders elect three directors at annual meetingJune 20, 2025 | investing.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from BrokeragesJune 17, 2025 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Bank of America Corp DEJune 10, 2025 | marketbeat.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comZentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational ProgressMay 14, 2025 | globenewswire.comFirst Patient Dosed With Azenosertib in Cyclin E1+ Ovarian CancerMay 3, 2025 | curetoday.comCZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2025 | globenewswire.comScott Dunseth Myers Purchases 21,000 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) StockMay 1, 2025 | insidertrades.comZentalis shares insights on cancer research at AACRApril 29, 2025 | investing.comZentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROCApril 28, 2025 | globenewswire.comZentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual MeetingApril 23, 2025 | globenewswire.comWhy Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 8.97%April 10, 2025 | aaii.comAWhy Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 12.58%April 2, 2025 | aaii.comAZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2025 | globenewswire.comStifel Nicolaus Sticks to Their Buy Rating for Zentalis Pharmaceuticals (ZNTL)March 27, 2025 | markets.businessinsider.comZentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational UpdatesMarch 26, 2025 | globenewswire.comZentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025March 25, 2025 | globenewswire.comZentalis presents updated clinical data on azenosertib as SGO 2025March 16, 2025 | markets.businessinsider.comZentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s CancerMarch 15, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGEMP, ZNTL, NLTX, and TELO Company DescriptionsGemphire Therapeutics NASDAQ:GEMPGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.Neoleukin Therapeutics NASDAQ:NLTX$19.50 -0.59 (-2.94%) As of 07/7/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Telomir Pharmaceuticals NASDAQ:TELO$1.18 +0.03 (+2.61%) As of 03:25 PM EasternTelomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.Zentalis Pharmaceuticals NASDAQ:ZNTL$1.25 +0.07 (+5.46%) As of 03:33 PM EasternZentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
